Related Experiment Video
Updated: May 15, 2025

08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
8.6K
Oral Manifestations of Multiple Sclerosis: A Systematic Review
Paula García-Rios1, Francisco Javier Rodríguez-Lozano1, Miguel Ramón Pecci-Lloret1
1Gerodontologý and Special Care Dentistry Unit, Faculty of Medicine, Morales Meseguer Hospital, University of Murcia, IMIB-Arrixaca, 30008 Murcia, Spain.
Journal of Clinical Medicine
|May 14, 2025
Summary
Multiple sclerosis (MS) is linked to oral health issues like dry mouth and gum disease. Early recognition and integrated care are crucial for managing these symptoms in MS patients.
Area of Science:
- Neurology
- Oral Medicine
- Autoimmune Diseases
Background:
- Multiple sclerosis (MS) is a chronic central nervous system autoimmune disease with varied symptoms.
- Oral manifestations in MS patients can stem from the disease itself or its treatments.
- Symptoms like xerostomia, periodontal disease, and dental sensitivity impact quality of life and are often overlooked.
Purpose of the Study:
- To systematically review oral manifestations in multiple sclerosis patients.
- To assess the prevalence and significance of these oral symptoms.
- To explore correlations between oral symptoms and MS clinical parameters (phenotype, duration, disability).
Main Methods:
- Systematic review adhering to PRISMA guidelines.
- Database search (PubMed, Scopus) for observational studies on MS and oral manifestations (last 10 years).
- Quality assessment using Newcastle-Ottawa Scale and JBI Critical Appraisal checklist.
Main Results:
- Ten studies were included, identifying hyposalivation, gingival inflammation, high DMFT/plaque indices, dental sensitivity, and oral pain as common.
- Significant associations found between oral dryness and MS phenotype (p < 0.05).
- Periodontal health showed significant links to disability levels (p < 0.05).
Conclusions:
- A clear association exists between MS and oral health issues, notably xerostomia and periodontal disease.
- Multidisciplinary care is essential for managing oral health in MS patients.
- Further research with standardized protocols is needed to clarify oral-systemic interactions in MS.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
996
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
996
Myasthenia Gravis: Diagnostic Tests
559
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
559
Parkinson's Disease: Overview
334
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
334

